Omega-3-carboxylic acids is a medication used with other medications to lower triglyceride levels in adult patients with severe hypertriglyceridemia. The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia.
- Mechanism
- Curator reviewed · 1 reference
The reduction of the synthesis of triglycerides in the liver may be caused because the main components of OM3-CA, eicosapentaenoic acid, and docosahexaenoic acid, are poor substrates for the enzymes responsible for the synthesis of triglycerides. These two major components inhibit the esterification of other fatty acids. OM3-CA is also thought to enhance the clearance of triglycerides from the circulating very low-density lipoprotein particles by different potential effects such as inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increase in mitochondrial and peroxisomal beta-oxidation in the liver, decrease lipogenesis in the liver and increase lipoprotein lipase activity.
- Primary indication
- OM3-CA is indicated as an adjunct to diet to reduce triglycerides levels in adults patients with severe hypertriglyceridemia (>500 mg/dL).Curator reviewed · 1 structured indication
- First approval
- United States, 2015
Resolves to
What you can answer from here — as of March 06, 2025
Which drugs share a target with Omega-3-carboxylic acids, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account